RI

RIBOMIC Inc.

Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.

4591 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区白金台3−16−13 白金台ウスイビル6階
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

RIBOMIC Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of aptamer therapeutics. The company utilizes its proprietary RiboART system, a unique platform technology, to generate first-in-class, molecularly targeted drugs using RNA aptamers. RIBOMIC's research and development pipeline focuses on addressing unmet medical needs in a range of therapeutic areas, including ophthalmic disorders, pain, fibrosis, bone diseases, and rare diseases. The company pursues its mission through internal drug development programs and strategic partnerships within the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-23 08:45
Prospectus
有価証券届出書(組込方式)
Japanese 326.2 KB
2025-06-20 03:50
Regulatory News Service
確認書
Japanese 7.9 KB
2025-06-20 03:49
Regulatory News Service
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 22.3 KB
2025-06-20 03:43
Annual Report
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2024-11-13 02:14
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-11-13 02:13
Interim Report
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 207.6 KB
2024-06-26 04:47
Regulatory News Service
臨時報告書
Japanese 22.7 KB
2024-06-26 04:45
Regulatory News Service
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 22.1 KB
2024-06-26 04:44
Regulatory News Service
確認書
Japanese 8.0 KB
2024-06-26 04:43
Annual Report
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 2.0 MB
2024-02-14 02:26
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-02-14 02:25
Quarterly Report
四半期報告書-第21期第3四半期(2023/10/01-2023/12/31)
Japanese 178.6 KB
2023-11-13 08:01
Regulatory News Service
確認書
Japanese 7.9 KB
2023-11-13 08:01
Quarterly Report
四半期報告書-第21期第2四半期(2023/07/01-2023/09/30)
Japanese 203.1 KB
2023-08-10 08:46
Report Publication Announcement
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all RIBOMIC Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for RIBOMIC Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Isofol Medical Logo
Developing a drug to enhance chemotherapy efficacy for solid tumors like colorectal cancer.
Sweden ISOFOL
B2B platform for Ukraine-Korea trade, investment, and post-war reconstruction.
South Korea 052770
IVISIONWORKS CO.,LTD. Logo
Accelerates social impact startups & develops digital therapeutics for cognitive rehabilitation.
South Korea 469750
A diversified, Asia-focused conglomerate with businesses in property, retail, auto, and more.
Bermuda N/A
The world's largest uranium producer, managing the front-end of the global nuclear fuel cycle.
Kazakhstan N/A
KAINOS MEDICINE, INC. Logo
Develops small molecule drugs for neurodegenerative diseases, cancers, and infectious diseases.
South Korea 284620
Kanamoto Co., Ltd. Logo
Global provider of rental construction equipment, also selling used machinery and steel products.
Japan 9678
Keihan Holdings Co.,Ltd. Logo
A conglomerate integrating transport, real estate, and retail for regional development.
Japan 9045
KNT-CT Holdings Co.,Ltd. Logo
A travel holding company offering themed tours and corporate travel solutions to boost Japan tourism.
Japan 9726
KoBioLabs, Inc. Logo
Develops AI-driven microbiome therapeutics for immune, metabolic, and brain disorders.
South Korea 348150

Talk to a Data Expert

Have a question? We'll get back to you promptly.